Cellular precOnditioning for Post-Surgical Myocardial Ischemic Complications - Observational Study (COSMIC)

April 2, 2024 updated by: Ottawa Hospital Research Institute

The goal of this observational study is to collect health data on people who are at high risk of having heart complications and are having a surgery that is not on the heart. The main questions it aims to answer are:

  • Is this study feasible in terms of recruiting enough people to participate in this study?
  • How often do heart complications happen in people who are at high risk of heart complications and are having a surgery that is not on the heart?

Participants will have their usual care and will also be asked to:

  • Have extra bloodwork done
  • Complete some surveys
  • Have two echocardiograms (ultrasounds of the heart)
  • Continue to follow-up with the research team for one year after their surgery

Researchers will compare how often heart complications occur in this high risk population to a future study where participants will receive stem cells before their surgery.

Study Overview

Status

Recruiting

Conditions

Detailed Description

This observational trial protocol is to collect baseline health data from participants undergoing intermediate to high-risk surgery and at high risk of developing perioperative myocardial ischemic complications for an upcoming Phase 1 trial that determines the feasibility of intravenous delivery of umbilical cord-derived (UC) mesenchymal stromal cells (MSCs) in the same patient population. Participants enrolled in this protocol, however, will not receive cell product; they will receive standard of care and serve as a lead in control group for the interventional study.

Study Type

Observational

Enrollment (Estimated)

12

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Meredith Conboy, MSc
  • Phone Number: 73800 613-737-8899
  • Email: mconboy@ohri.ca

Study Contact Backup

  • Name: Manoj M Lalu, MD, PhD
  • Phone Number: 75083 613-737-8899
  • Email: mlalu@toh.ca

Study Locations

    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Recruiting
        • The Ottawa Hospital
        • Principal Investigator:
          • Manoj M Lalu, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Participants will be recruited from the Ottawa Hospital

Description

Inclusion Criteria:

A participant must meet all 5 inclusion criteria to be eligible:

  • Referred for elective intermediate to high risk noncardiac surgery as defined by the American Heart Association guidelines (e.g., intrathoracic, open intraabdominal, or open vascular surgery)
  • 45 years of age or older
  • Revised cardiac risk index ≥ 2
  • NT-proBNP level of ≥ 200 pg/mL
  • Able to provide informed consent

Exclusion Criteria:

  • Experience an acute coronary syndrome, myocardial infarction, heart failure, or stroke within preceding 3 months
  • Coronary revascularization anticipated during the study period
  • Severe mitral/aortic valve stenosis
  • Evidence of clinically significant arrhythmia in last three months.
  • Major surgical procedure in previous 3 months
  • History of malignancy requiring surgery, chemotherapy, immunotherapy, or radiation within previous 5 years
  • Ongoing malignancy requiring surgical resection
  • Women who are pregnant, breastfeeding, or of childbearing potential who are unable to use a medically acceptable form of contraception throughout the study
  • Received any experimental cell therapy previously
  • Unable to provide written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of Participant Recruitment
Time Frame: 1 year
Our primary outcome is the feasibility of participant recruitment. This will be determined by measurements of recruitment efficiency: 1) proportion of potentially eligible participants that are successfully screened; 2) proportion of participants successfully screened who do not enroll (reason for failure to enroll will be recorded).
1 year
Baseline Frequency of adverse events and serious adverse events
Time Frame: 1 year
To determine the baseline frequency of adverse events and serious adverse events in this high risk population
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of life of participants
Time Frame: 1 year
The EQ-5D-5L questionnaire will be used. This questionnaire measures quality of life using five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Manoj M Lalu, MD, PhD, The Ottawa Hospital Research Institute, The Ottawa Hospital, University of Ottawa

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 15, 2023

Primary Completion (Estimated)

September 1, 2024

Study Completion (Estimated)

September 1, 2025

Study Registration Dates

First Submitted

February 8, 2023

First Submitted That Met QC Criteria

March 8, 2023

First Posted (Actual)

March 9, 2023

Study Record Updates

Last Update Posted (Actual)

April 3, 2024

Last Update Submitted That Met QC Criteria

April 2, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 20220330-01H

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.